Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals
London (ots/PRNewswire) - Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK. About Hikma ...